文献速递乳腺癌

瑞波西利联合内分泌治疗用于绝经前HR阳性晚期乳腺癌(MONALEESA-7):随机3期试验

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
PubMed 文献 · Lancet Oncol · 2018-05-24

MONALEESA-7是一项在30国188中心开展的随机双盲安慰剂对照3期试验,纳入672例绝经前HR阳性HER2阴性晚期乳腺癌患者,比较瑞波西利或安慰剂联合内分泌治疗(他莫昔芬或非甾体芳香化酶抑制剂)加戈舍瑞林。

要点

  • 瑞波西利联合内分泌治疗显著改善绝经前HR阳性晚期乳腺癌的无进展生存期。
  • 常见3/4级不良事件为中性粒细胞减少(61% vs 4%)和白细胞减少(14% vs 1%)。

核心结论

  • 瑞波西利联合内分泌治疗较安慰剂联合内分泌治疗显著延长绝经前HR阳性HER2阴性晚期乳腺癌患者的无进展生存期,且安全性可控。

研究设计与样本

  • 3期随机双盲安慰剂对照试验,在30个国家188个中心开展,纳入672例绝经前HR阳性HER2阴性晚期乳腺癌患者,按1:1随机分配至瑞波西利组(335例)或安慰剂组(337例)。
  • 主要终点为研究者评估的无进展生存期,采用意向性分析;安全性分析纳入至少接受一剂研究治疗的所有患者。

主要发现

  • 3/4级不良事件发生率>10%者:中性粒细胞减少(瑞波西利组203/335例[61%],安慰剂组12/337例[4%])和白细胞减少(48例[14%] vs 4例[1%])。
  • 严重不良事件:瑞波西利组60/335例(18%),安慰剂组39/337例(12%);因不良事件终止治疗者分别为12例(4%)和10例(3%)。
  • 治疗期间或治疗结束后30天内死亡11例(瑞波西利组5例[1%],安慰剂组6例[2%]),多数死于乳腺癌进展(3例[1%] vs 6例[2%]);瑞波西利组另2例死亡分别归因于抗凝患者颅内出血和既往伤口出血。

临床怎么用

  • 瑞波西利联合内分泌治疗(他莫昔芬或非甾体芳香化酶抑制剂)加戈舍瑞林可作为绝经前HR阳性HER2阴性晚期乳腺癌患者的新一线治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer. MONALEESA-7 aimed to assess the efficacy and safety of ribociclib plus endocrine therapy in premenopausal women with advanced, HR-positive breast cancer. METHODS: This phase 3, randomised, double-blind, placebo-controlled trial was done at 188 centres in 30 countries. Eligible patients were premenopausal women aged 18-59 years who had histologically or cytologically confirmed HR-positive, HER2-negative, advanced breast cancer; an Eastern Cooperative Oncology Group performance status of 0 or 1; measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 criteria, or at least one predominantly lytic bone lesion; and had not received previous treatment with cyclin-dependent kinases 4 and 6 inhibitors. Endocrine therapy and chemotherapy in the adjuvant or neoadjuvant setting was permitted, as was up to one line of chemotherapy for advanced disease. Patients were randomly assigned (1:1) via interactive response technology to receive oral ribociclib (600 mg/day on a 3-weeks-on, 1-week-off schedule) or matching placebo with either oral tamoxifen (20 mg daily) or a non-steroidal aromatase inhibitor (letrozole 2·5 mg or anastrozole 1 mg, both oral, daily), all with goserelin (3·6 mg administered subcutaneously on day 1 of every 28-day cycle). Patients and investigators were masked to treatment assignment. Efficacy analyses were by intention to treat, and safety was assessed in all patients who received at least one dose of any study treatment. The primary endpoint was investigator-assessed progression-free survival. MONALEESA-7 is registered with ClinicalTrials.gov, NCT02278120 and is ongoing, but no longer enrolling patients. FINDINGS: Between Dec 17, 2014, and Aug 1, 2016, 672 patients were randomly assigned: 335 to the ribociclib group and 337 to the placebo group. Per investigator's assessment, median progression-free survival was 23·8 months (95% CI 19·2-not reached) in the ribociclib group compared with 13·0 months (11·0-16·4) in the placebo group (hazard ratio 0·55, 95% CI 0·44-0·69; p<0·0001). Grade 3 or 4 adverse events reported in more than 10% of patients in either group were neutropenia (203 [61%] of 335 patients in the ribociclib group and 12 [4%] of 337 in the placebo group) and leucopenia (48 [14%] and four [1%]). Serious adverse events occurred in 60 (18%) of 335 patients in the ribociclib group and 39 (12%) of 337 in the placebo group, of which 15 (4%) and six (2%), respectively, were attributed to the study regimen. 12 (4%) of 335 patients in the ribociclib group and ten (3%) of 337 in the placebo group discontinued treatment because of adverse events. No treatment-related deaths occurred. 11 deaths occurred (five [1%] in the ribociclib group and six [2%] in the placebo group) during or within 30 days after treatment, most of which were due to progression of the underlying breast cancer (three [1%] and six [2%]). The remaining two deaths in the ribociclib group were due to an intracranial haemorrhage in an anticoagulated patient, and a pre-existing wound haemorrhage in another patient. INTERPRETATION: Ribociclib plus endocrine therapy improved progression-free survival compared with placebo plus endocrine therapy, and had a manageable safety profile in patients with premenopausal, HR-positive, HER2-negative, advanced breast cancer. The combination could represent a new first-line treatment option for these patients. FUNDING: Novartis.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018. PMID: 29804902. doi:10.1016/S1470-2045(18)30292-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。